• Human tonsil stained with anti-CD23 antibody using peroxidase-conjugate and DAB chromogen. Note the membranous staining of follicular dendritic cells.

Anti-CD23 antibody (48-321aa) [ZM209] (STJ180394)

SKU:
STJ180394

Shipping:
Free Shipping
Current Stock:
Host: Mouse
Applications: IHC-P
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Mouse monoclonal antibody anti-CD23 (48-321aa) is suitable for use in Immunohistochemistry research applications.
Clonality: Monoclonal
Clone ID: ZM209
Conjugation: Unconjugated
Isotype: IgG2b/Kappa
Formulation: Tris-HCI buffer containing stabilizing protein (BSA) and <0.1% ProClin
Purification: Affinity purified
Dilution Range: 1:50
Storage Instruction: Store at 2‐8°C for up to 24 months. Predilute: Ready to use, no reconstitution necessary. Concentrate: Use dilution range and appropriate lab‐standardized diluent. Stability after dilution: 7 days at 24°C, 3 months at 2‐8°C, 6months at ‐20°C.
Immunogen Region: 48-321aa
Specificity: Positive control: Tonsil
Immunogen: Recombinant fragment (around aa 48-321) of human FCER2/CD23 protein
Background CD23 (FCE2) is a type II integral membrane glycoprotein that is expressed on mature B cells, monocytes, eosinophils, platelets and dendritic cells. CD23 associates as an oligomer where cooperative binding of at least two lectin domains is required for high affinity IgE binding to CD23. It may play a role in antigen presentation by B cells by interacting with CD40. CD23 has been shown to be associated with the Fyn tyrosine kinase. The truncated molecule can be secreted, then function as a potent mitogenic growth factor. CD23 is expressed on a subpopulation of peripheral blood cells, B-lymphocytes and on EBV transformed B lymphoblastoid cell lines. CD23 is also detected in neoplastic cells from cases of B cell chronic lymphocytic leukemia.

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance